The Q1 results are backward-looking and secondary to the June 18 FDA decision on tebipenem HBr. Monitor for any pre-PDUFA documents or commentary. Approval could trigger milestone payments and a re-rating; denial would likely require strategic alternatives given minimal revenue.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $2.76entry
- T+1 · 6mo ago +1.09%α +2.31% · $2.79
- T+5 · 6mo ago −2.54%α −1.82% · $2.69
- T+20 · 5mo ago +3.26%α +4.12% · $2.85
- T+60 · 3mo ago −55.43%α −59.02% · $1.23
Price Chart
How similar events traded
Executive Summary
Spero Therapeutics reported Q1 2026 results with revenue plunging 95% to $0.3M as the Phase 3 trial ended, but net loss narrowed to $7.2M from $13.9M due to lower R&D expenses. Cash position grew to $56.1M, and guidance for runway into 2028 was reaffirmed. The market remains focused on the June 18 PDUFA decision for tebipenem HBr, which will determine the company's near-term trajectory.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $7.2M vs $13.9M in Q1 2025 (narrowed 48%)
- Diluted EPS: -$0.13 vs -$0.25 year over year
- Total revenue fell to $0.3M from $5.9M, a 95% decline
- R&D expenses dropped to $2.9M from $13.6M as PIVOT-PO trial completed
- Cash and cash equivalents: $56.1M at March 31, 2026, up from $40.3M at year-end
- Cash runway guidance maintained into 2028
- PDUFA date for tebipenem HBr NDA remains June 18, 2026
- GSK is the licensing partner for tebipenem HBr commercialization
Financial Impact
Revenue collapsed to near zero as collaboration milestones concluded; operating loss improved by ~$7M as clinical trial costs fell. No change to cash runway guidance.
Risk Factors
- FDA denial or complete response letter for tebipenem HBr
- Revenue dependence on GSK milestones; no approved products
- Dilution risk if additional financing needed post-PDUFA decision
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-221567 |
| Document: d147628d8k.htm | 0001193125-26-221567 |
| Document: 0001193125-26-221567-index-headers.html | 0001193125-26-221567 |
| Document: 0001193125-26-221567-index.html | 0001193125-26-221567 |
| Document: 0001193125-26-221567.txt | 0001193125-26-221567 |
| 8-K Data (Synthetic) | 0001193125-26-221567 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers